X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (108) 108
phenylthiohydantoin - analogs & derivatives (106) 106
male (103) 103
index medicus (96) 96
prostate cancer (88) 88
phenylthiohydantoin - pharmacology (53) 53
animals (51) 51
prostatic neoplasms, castration-resistant - drug therapy (48) 48
cell line, tumor (44) 44
enzalutamide (44) 44
cancer (43) 43
oncology (43) 43
phenylthiohydantoin - therapeutic use (43) 43
androgen receptor (39) 39
mice (39) 39
androgens (38) 38
urology & nephrology (38) 38
metastasis (37) 37
prostate (37) 37
endocrinology & metabolism (33) 33
castration (32) 32
chemotherapy (31) 31
receptors, androgen - metabolism (31) 31
prostatic neoplasms - drug therapy (30) 30
antineoplastic agents - therapeutic use (27) 27
prostatic neoplasms, castration-resistant - pathology (27) 27
prostatic neoplasms - pathology (26) 26
aged (25) 25
abiraterone (24) 24
middle aged (24) 24
increased survival (23) 23
phenylthiohydantoin - administration & dosage (22) 22
receptors, androgen - genetics (22) 22
analysis (21) 21
progression (21) 21
prostatic neoplasms, castration-resistant - metabolism (21) 21
drug resistance, neoplasm (19) 19
expression (19) 19
article (18) 18
prostatic neoplasms - metabolism (18) 18
therapy (18) 18
antineoplastic agents - pharmacology (17) 17
care and treatment (17) 17
docetaxel (17) 17
signal transduction - drug effects (17) 17
abiraterone acetate (16) 16
androgen antagonists - pharmacology (16) 16
cell proliferation - drug effects (16) 16
gene expression (16) 16
metastases (16) 16
multidisciplinary sciences (16) 16
tumors (16) 16
xenograft model antitumor assays (16) 16
aged, 80 and over (15) 15
disease progression (15) 15
drug resistance, neoplasm - drug effects (15) 15
antitumor-activity (14) 14
phenylthiohydantoin - adverse effects (14) 14
resistance (14) 14
retrospective studies (14) 14
survival (14) 14
xenografts (14) 14
androstenes - therapeutic use (13) 13
mice, nude (13) 13
prostatic neoplasms - genetics (13) 13
androgen receptor antagonists - pharmacology (12) 12
apoptosis (12) 12
cancer therapies (12) 12
development and progression (12) 12
prostatic neoplasms, castration-resistant - genetics (12) 12
treatment outcome (12) 12
urology (12) 12
apoptosis - drug effects (11) 11
drug resistance (11) 11
prognosis (11) 11
prostatic neoplasms, castration-resistant - mortality (11) 11
science (11) 11
splice variants (11) 11
taxoids - therapeutic use (11) 11
antiandrogen (10) 10
deprivation (10) 10
female (10) 10
gene expression regulation, neoplastic - drug effects (10) 10
inhibition (10) 10
mechanisms (10) 10
neoplasm metastasis (10) 10
orchiectomy (10) 10
prostate-cancer (10) 10
research (10) 10
transcription (10) 10
urologic and male genital diseases (10) 10
antineoplastic agents - administration & dosage (9) 9
cell survival (9) 9
cells (9) 9
drug therapy (9) 9
medical prognosis (9) 9
patients (9) 9
signal transduction (9) 9
activation (8) 8
androgen antagonists - therapeutic use (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Immunology, ISSN 0161-5890, 1988, Volume 25, Issue 4, pp. 403 - 410
The characterization of the major antigenic determinants present in human protamine P1 has been carried out by the use of specific rabbit polyclonal and mouse... 
Amino Acid Sequence | Epitopes - analysis | Rabbits | Enzyme-Linked Immunosorbent Assay | Humans | Molecular Sequence Data | Male | Chromatography, High Pressure Liquid | Phenylthiohydantoin | Protamines - analysis | Protamines - immunology | Animals | Mice | Cyanogen Bromide | Peptides - analysis
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e53701
Despite advances in detection and therapy, castration-resistant prostate cancer continues to be a major clinical problem. The aberrant activity of stem cell... 
IN-VITRO | STEM-LIKE CELLS | MECHANISM | MULTIDISCIPLINARY SCIENCES | GROWTH | SELF-RENEWAL | NANOG | DIFFERENTIATION | IDENTIFICATION | EXPRESSION | CARCINOMA | Embryonic Stem Cells - metabolism | Epithelial Cells - metabolism | Epithelial Cells - drug effects | Humans | Receptors, Androgen - metabolism | Male | RNA, Messenger - metabolism | Prostate - metabolism | SOXB1 Transcription Factors - metabolism | Prostate - pathology | Neoplasm Metastasis | Prostatic Neoplasms - genetics | SOXB1 Transcription Factors - genetics | Prostate - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Repressor Proteins - metabolism | Phenylthiohydantoin - pharmacology | Prostatic Neoplasms - pathology | Tumor Suppressor Proteins - metabolism | Prostatic Neoplasms - surgery | RNA, Messenger - genetics | Androgen Antagonists - pharmacology | Repressor Proteins - genetics | Epithelial Cells - pathology | Signal Transduction - genetics | Phenylthiohydantoin - analogs & derivatives | Orchiectomy | Transcription Factors - metabolism | Animals | Embryonic Stem Cells - drug effects | Signal Transduction - drug effects | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Drug Resistance, Neoplasm - drug effects | Androgens | Chromatin | Genetic aspects | Fibroblast growth factors | Embryonic stem cells | Prostate cancer | Cancer | Fibroblast growth factor | Epithelial cells | Embryo cells | Tumor cell lines | Kinases | Embryos | Metastases | Fibroblast growth factor 5 | Signal transduction | Signaling | Pathways | Castration | Medical prognosis | Stem cells | Aberration | Prostate | Tumors
Journal Article
Nature, ISSN 0028-0836, 07/2015, Volume 523, Issue 7560, pp. 347 - 351
Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5... 
ANDROGEN RECEPTOR | 3-BETA-HYDROXYSTEROID DEHYDROGENASE | CYP17A1 INHIBITION | MECHANISM | TESTOSTERONE | RATIONALE | MULTIDISCIPLINARY SCIENCES | INCREASED SURVIVAL | CHEMOTHERAPY | EXPOSURE | ENZALUTAMIDE | Chromatin - metabolism | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Androgens - biosynthesis | Male | Androstenes - pharmacology | Androgen Receptor Antagonists - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Biotransformation | Cell Division | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - metabolism | 3-Hydroxysteroid Dehydrogenases - metabolism | Prostatic Neoplasms - drug therapy | Dihydrotestosterone - metabolism | Phenylthiohydantoin - pharmacology | Prostatic Neoplasms - pathology | Androstenes - therapeutic use | 5-alpha Reductase Inhibitors - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Phenylthiohydantoin - analogs & derivatives | Androgen Receptor Antagonists - metabolism | Xenograft Model Antitumor Assays | Androstenes - chemistry | Animals | Biosynthetic Pathways - drug effects | Survival Analysis | 5-alpha Reductase Inhibitors - pharmacology | Androstenes - metabolism | Prostatic Neoplasms - enzymology | Mice | Steroid 17-alpha-Hydroxylase - metabolism | 5-alpha Reductase Inhibitors - metabolism | Androgens - metabolism | Enzymes | Testosterone | Androgens | Metabolites | Ligands | Gene expression | Prostate cancer | Tumors
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4046 - 4054
Purpose: Several lines of evidence support targeting the androgen signaling pathway in breast cancer. Enzalutamide is a potent inhibitor of androgen receptor... 
ANDROGEN RECEPTOR | MASS-SPECTROMETRY METHOD | PLASMA | EXEMESTANE | ANTIANDROGEN | ONCOLOGY | FULVESTRANT | PROSTATE-CANCER | AROMATASE INHIBITORS | ER-ALPHA | ANASTROZOLE | Phenylthiohydantoin - adverse effects | Triazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Progesterone - genetics | Drug-Related Side Effects and Adverse Reactions - pathology | Antineoplastic Agents, Hormonal - pharmacokinetics | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Cytochrome P-450 CYP3A - genetics | Postmenopause | Adult | Female | Aromatase Inhibitors - administration & dosage | Receptors, Estrogen - genetics | Antineoplastic Agents, Hormonal - administration & dosage | Breast Neoplasms - drug therapy | Phenylthiohydantoin - analogs & derivatives | Phenylthiohydantoin - administration & dosage | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Aged | Neoplasm Staging | Drug-Related Side Effects and Adverse Reactions - classification | Phenylthiohydantoin - pharmacokinetics | Cytochrome | Anastrozole | Estrogens | Cytochrome P450 | Estrogen | Estrogen receptors | Breast cancer | Pharmacology | Exposure | Patients | Fulvestrant | Signal transduction | Signaling | Androgens | Experimental design | Safety engineering | Breast | Progesterone | Prostate cancer | Prostate | Cancer
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 06/2018, Volume 78, Issue 12, pp. 3147 - 3162
Enzalutamide is a second-generation nonsteroidal antiandrogen clinically approved for the treatment of castration-resistant prostate cancer (CRPC), yet... 
ANDROGEN RECEPTOR | RECEPTOR SPLICE VARIANTS | STEM-CELLS | ACTIVATION | ONCOLOGY | MECHANISMS | THERAPIES | INDUCTION | BETA-CATENIN | PROGRESSION | AXIS | Up-Regulation | Androgen Receptor Antagonists - therapeutic use | Phenylthiohydantoin - therapeutic use | Humans | Receptors, Androgen - metabolism | Male | Androgen Receptor Antagonists - pharmacology | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Prostate - pathology | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Pyrimidinones - pharmacology | Phenylthiohydantoin - pharmacology | Datasets as Topic | Pyrimidinones - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | beta Catenin - metabolism | Phenylthiohydantoin - analogs & derivatives | Xenograft Model Antitumor Assays | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Wnt Signaling Pathway - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | beta Catenin - antagonists & inhibitors | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Drug Resistance, Neoplasm - drug effects | Cell proliferation | Therapy | Wnt protein | Drug resistance | Augmented reality | Molecular chains | β-catenin | Ubiquitination | Molecular modelling | Castration | Failure analysis | Inhibition | Prostate cancer | Prostate | Bioinformatics | Cancer | androgen receptor | castration-resistant prostate cancer | cancer stem cell | enzalutamide resistance
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 9, pp. 2169 - 2176
Purpose: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or... 
THERAPY | ANTIANDROGEN | ONCOLOGY | RESISTANCE | PHASE-II | RADICAL PROSTATECTOMY | INCREASED SURVIVAL | CANCER | CHEMOTHERAPY | PROGRESSION | ABIRATERONE | Neoplasm, Residual - pathology | Phenylthiohydantoin - adverse effects | Prostatic Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Combined Modality Therapy | Neoplasm, Residual - blood | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Phenylthiohydantoin - administration & dosage | Receptors, Androgen - genetics | Leuprolide - administration & dosage | Neoadjuvant Therapy - adverse effects | Prostatic Neoplasms - blood | Prostatectomy | Aged | Neoplasm, Residual - chemically induced | Dutasteride - administration & dosage | Prostatic Neoplasms - drug therapy | Therapy | Risk groups | Health risks | Minimal residual disease | Patients | Anticancer properties | Testosterone | Signaling | Dihydrotestosterone | Androgens | Flutamide | Experimental design | Luteinizing hormone | Luteinizing hormone-releasing hormone | Antitumor activity | Prostate cancer | Prostate | Cancer | dutasteride | neoadjuvant | NEW MOLECULAR TARGETS | THERAPEUTICS: Cellular responses to anticancer drugs | CL01 PHASE I – III CLINICAL TRIALS: Phase I–III Trials_Genitourinary cancers: prostate | ET02 MECHANISMS OF DRUG ACTION | enzalutamide
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2018, Volume 13, Issue 6, pp. e0198389 - e0198389
Background Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential... 
CELLS | RECEPTOR SPLICE VARIANTS | INHIBITION | MULTIDISCIPLINARY SCIENCES | ANDROGEN-RECEPTOR | CLINICAL-TRIALS | THERAPY RESISTANCE | KAPPA-B PATHWAY | INCREASED SURVIVAL | PROGRESSION | ABIRATERONE | Phenylthiohydantoin - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Niclosamide - pharmacokinetics | Male | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Phenylthiohydantoin - analogs & derivatives | Prostatic Neoplasms, Castration-Resistant - pathology | Dose-Response Relationship, Drug | Phenylthiohydantoin - administration & dosage | Maximum Tolerated Dose | Neoplasm Metastasis | Niclosamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Aged | Cell Proliferation - drug effects | Niclosamide - adverse effects | Drug Resistance, Neoplasm - drug effects | Phenylthiohydantoin - pharmacokinetics | Anthelmintics | Dosage and administration | Drug therapy, Combination | Drug therapy | Prostate cancer | Methods | Testing | Alternative splicing | Wnt protein | Toxicity | Niclosamide | Oncology | Biology | Metastasis | Drug resistance | Metastases | Castration | Vomiting | Safety | Drug dosages | Medical research | Tumor cells | Diarrhea | Nausea | Pharmacology | Bioavailability | Patients | Augmented reality | Constraining | Medicine | Androgens | Ligands | Colitis | Mutation | Pharmacokinetics | Prostate | Cancer | Index Medicus | Slopes
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2017, Volume 23, Issue 3, pp. 726 - 734
Purpose: We evaluated the association of PSA and androgen receptor splice variant-7 (AR-V7) transcript levels in patients' blood with time to treatment failure... 
ANDROGEN-DEPRIVATION THERAPY | DROPLET DIGITAL PCR | POLYMERASE-CHAIN-REACTION | ONCOLOGY | RESISTANCE | RECEPTOR | MECHANISMS | PROGNOSTIC-SIGNIFICANCE | INCREASED SURVIVAL | SPLICE VARIANTS | CHEMOTHERAPY | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prognosis | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Male | RNA, Neoplasm - blood | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Prostatic Neoplasms - blood | Kallikreins - blood | Retrospective Studies | Prostatic Neoplasms - drug therapy | Prostate-Specific Antigen - genetics | Adenocarcinoma - blood | Kallikreins - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Abiraterone Acetate - therapeutic use | Adenocarcinoma - drug therapy | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Biomarkers, Tumor - blood | Androgens | Neoplasms, Hormone-Dependent - blood | RNA, Messenger - blood | Receptors, Androgen - genetics | Androgen Antagonists - therapeutic use | Aged | Neoplasms, Hormone-Dependent - drug therapy | Protein Isoforms - genetics | Alternative splicing | Statistical analysis | Transcription | Tumor cells | Prostate-specific antigen | Regression analysis | Gene expression | Ribonucleic acid--RNA | Patients | Blood | Confidence intervals | Castration | Experimental design | Medical prognosis | Peripheral blood | Biomarkers | Acetic acid | Prostate cancer | Prostate | Cancer
Journal Article
Journal Article